RNAi Therapeutics News and Research

RSS
RNA interference (RNAi) was discovered less than a decade ago and already there are human clinical trials in progress or planned. A major advantage of RNAi versus other anti-sense based approaches for therapeutic applications is that it utilizes cellular machinery that efficiently allows targeting of complementary transcripts, often resulting in highly potent down-regulation of gene expression.
Intradigm issued new RNAi therapeutics patent

Intradigm issued new RNAi therapeutics patent

Designer RNA fights high cholesterol, medical researchers find

Designer RNA fights high cholesterol, medical researchers find

Roche acquires Mirus to advance RNAi delivery research

Roche acquires Mirus to advance RNAi delivery research

Roche and Alnylam form RNAi therapeutics alliance

Roche and Alnylam form RNAi therapeutics alliance

Two drug giants team up to develop new bird flu therapy

Two drug giants team up to develop new bird flu therapy

Sirna Therapeutics awarded patent covering large-scale synthesis of RNAi-based therapeutics

Sirna Therapeutics awarded patent covering large-scale synthesis of RNAi-based therapeutics

Benitec receives exclusive rights to use DNA technology pioneered at Stanford University for all RNAi therapeutic uses

Benitec receives exclusive rights to use DNA technology pioneered at Stanford University for all RNAi therapeutic uses

Benitec acquires Avocel to focus on rapid development of hepatitis C therapeutics

Benitec acquires Avocel to focus on rapid development of hepatitis C therapeutics